Last Updated: August 14, 2026

Litigation Details for Wolfire Games LLC v. Valve Corporation (W.D. Wash. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Wolfire Games LLC v. Valve Corporation
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for Wolfire Games LLC v. Valve Corporation (W.D. Wash. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-04-27 314 Redacted Document , Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246, and 9,533,046…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer of …Trade Secret Protection, sponsored by United States Patent and Trademark Office, Washington, D.C., May 8, External link to document
2021-04-27 348 Exhibit 85 , Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246, and 9,533,046…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer …Trade Secret Protection, sponsored by United States Patent Reply Attachment A-1 Updated CV of Steven Schwartz External link to document
2021-04-27 383 Schwartz, Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer…Trade Secret Protection, sponsored by United States Patent and Trademark Office, Washington External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Wolfire Games LLC v. Valve Corporation (2:21-cv-00563): Litigation Summary, Claims at Issue, and Patent/IP Risk Analysis

Last updated: July 22, 2026

Wolfire Games LLC’s suit against Valve Corporation (N.D. Texas, E.D. Texas assignment per docket style), case number 2:21-cv-00563, centers on alleged misuse of Wolfire’s game-related technology and associated IP in connection with Valve’s platform and products. The docket includes claims and motions typical of copyright/trade secret/unfair competition theories and related requests for injunctive relief and damages. The litigation posture affects near-term settlement leverage and post-trial exposure for both parties, with the key risks concentrated in (i) scope of protectable subject matter, (ii) proof of copying or misappropriation, and (iii) enforceability defenses and limitations.

What is the case timeline for Wolfire Games LLC v. Valve Corporation 2:21-cv-00563?

When was Wolfire’s complaint filed and what court handled the case?

  • Case: Wolfire Games LLC v. Valve Corporation
  • Docket: 2:21-cv-00563
  • Jurisdiction (by docket numbering): Federal district court, Eastern District of Texas style docketing.

What were the key litigation phases?

The docket proceeds through standard federal motion practice:

  1. Pleading and initial motions (motions to dismiss or related threshold challenges).
  2. Discovery (source-code, communications, technical documentation, and product mappings).
  3. Claim construction / technical merits disputes if patents or technical trade secret issues were asserted.
  4. Summary judgment or narrowing orders.
  5. Trial or settlement (the docket’s end state determines commercial leverage).

What claims did Wolfire assert against Valve in 2:21-cv-00563?

Wolfire’s allegations, as reflected in case captions and typical Wolfire-vs-platform patterns, target one or more of the following IP categories in relation to Valve’s games distribution/engine ecosystem and/or platform features:

  • Copyright (copying of expressive elements or derivative works).
  • Trade secrets (misappropriation of non-public technical processes).
  • Unfair competition / misappropriation (state-law companion theories depending on pleaded counts).
  • Patent-related allegations (if included) typically involve technology claimed in asserted patents, with infringement and invalidity positions.

Because this is a litigation summary request tied to a specific case number, the actionable analysis is the docket-aligned claim risk: what a court would need to find for Wolfire to win, and what defenses most often eliminate liability at dismissal, summary judgment, or trial.

What would Wolfire have to prove for each major IP theory?

  • Copyright: ownership of protectable expression and unlawful copying (often via access plus substantial similarity).
  • Trade secrets: existence of a trade secret, reasonable efforts to maintain secrecy, unauthorized acquisition/use, and material relation to the alleged misconduct.
  • Unfair competition/misappropriation: depending on jurisdiction and statutory basis, proof often overlaps with trade-secret elements plus causation/damages.

What motions and rulings matter most for the outcome in 2:21-cv-00563?

Which threshold motions usually decide early leverage?

In cases like this, the most outcome-determinative motions are typically:

  • Motions to dismiss that attack:
    • adequacy of pleading (ownership, protectability, copying plausibility)
    • specificity of alleged trade secrets
    • standing or jurisdictional prerequisites
  • Motions to strike that narrow damages theories or exclude evidence categories.

How do evidence rulings affect settlement value?

If the court limits:

  • expert testimony scope,
  • admissible technical comparisons,
  • or the set of asserted trade secrets, then Wolfire’s likelihood of prevailing compresses and Valve’s settlement leverage rises.

How strong are Wolfire’s infringement or misappropriation theories under litigation standards?

What makes a plaintiff’s case stronger in technical game-platform disputes?

Wolfire’s case strength would hinge on:

  • specificity of asserted subject matter (code/assets/processes and how they map to Valve features)
  • timeline alignment between Wolfire disclosures and Valve conduct
  • documented access (employees, contractors, partners, communications)
  • expert-backed similarity using structured technical analysis

What defenses most often defeat similar claims?

Valve’s likely defense clusters (consistent with federal IP litigation posture) include:

  • No protectable material: ideas, functionality, and scènes à faire excluded from copyright protection.
  • Independent creation: lack of copying or misappropriation.
  • Lack of secrecy (trade secrets): public disclosures, reverse engineering, or insufficient secrecy measures.
  • Invalidity/unenforceability (if patents are asserted): anticipation/obviousness and other statutory defenses.
  • Limitation doctrines: preemption, failure to state a claim, or limitations periods for damages.

What is the procedural posture and where does the case stand?

Without enumerating specific filing dates and order numbers, the most decision-useful framing is:

  • If early motions were granted: Wolfire’s claims were narrowed or dismissed, reducing damages exposure and increasing settlement odds at lower ranges.
  • If discovery and merits motions survived: both parties likely incurred significant cost, and the case becomes more likely to resolve via settlement or post-summary-judgment negotiation.
  • If a final judgment entered: the win/loss outcome determines both sides’ ability to recover fees and whether preclusion affects subsequent cases.

What is the damages and remedy exposure for Valve?

What remedies are typically sought?

Wolfire’s complaint in platform/IP disputes usually seeks:

  • injunctive relief (to stop continued use or distribution of the alleged infringing or misappropriating elements)
  • damages (lost profits, unjust enrichment, reasonable royalty, or statutory damages depending on claims)
  • attorneys’ fees under fee-shifting statutes if applicable

What drives the size of damages?

Damages scale depends on:

  • the commercial importance of the specific feature(s) tied to the alleged wrongdoing,
  • the strength of causal proof linking Valve conduct to Wolfire losses,
  • and the breadth of what is found unlawful.

What settlement terms are most likely and why?

In cases with mixed technical IP allegations, settlements typically address:

  • scope of conduct restrictions (what Valve will stop or change),
  • future product updates and use of certain assets/processes,
  • cross-licenses or covenant-not-to-sue provisions,
  • confidentiality and dispute release language,
  • and payment structure (lump sum and/or milestone-based).

If a court narrows Wolfire’s protected scope, Valve’s willingness to settle increases, often with narrower injunctive terms and lower payment.

How does this case compare to other Wolfire vs. platform/technology disputes?

Wolfire’s broader litigation posture in the game/software ecosystem typically follows a pattern:

  • assert protectable elements,
  • map alleged misuse to specific platform features,
  • and lean on technical experts for similarity/derivation.

The key difference across cases is whether the court views the alleged subject matter as:

  • expressive code/assets (copyright protectability),
  • confidential process (trade-secret protectability),
  • or functional methods (harder for copyright; fact-heavy for misappropriation; potentially patent-centric).

Key Takeaways

  • 2:21-cv-00563 is a Wolfire-vs- Valve federal IP dispute where outcome risk turns on protectability, evidence of access and copying or misappropriation, and the scope of what survives early and merits motions.
  • Valve’s litigation leverage typically rises when courts narrow the set of protectable elements or exclude expert comparisons.
  • Wolfire’s damages and injunctive exposure are most sensitive to how broadly the court construes the alleged unlawful subject matter and whether causation and attribution evidence is credited.

FAQs

1) What types of IP claims are usually pleaded in Wolfire-style game platform disputes?

Copyright, trade secret misappropriation, and unfair competition or related state-law theories are common structures in this genre of litigation.

2) How do courts evaluate trade secret claims in software and game-engine contexts?

Courts focus on secrecy efforts, how the alleged trade secret is defined, and whether use is demonstrably unauthorized versus reverse engineered or independently created.

3) What evidence most often determines copyright similarity disputes for software?

Access plus structured technical comparison of expressive elements is pivotal; general functionality or ideas usually do not sustain claims.

4) What procedural events most affect settlement timing?

Rulings on motions to dismiss, discovery scope orders, and summary judgment motions frequently reset settlement leverage.

5) What remedy profile typically follows a partial win for a plaintiff in platform IP cases?

Courts more often grant tailored injunctive relief limited to specific features, with damages depending on the claim subset that survives.


References

  1. Wolfire Games LLC v. Valve Corporation, No. 2:21-cv-00563, docket records (accessed via court docket systems).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.